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cases for disease development22, 23 and has 
also recently been described in NPHP. 24 
The increasing number of JSRD genes, the 
variable phenotype only partly associated 
with genic and allelic eﬀects, plus cases 
with missing mutations, indicate that this 
step toward complex inheritance is also a 
possibility in JSRD.
The overlapping phenotypes of JSRD, 
MKS, NPHP, and SLS, plus the overlap-
ping group of genes involved in causing 
these diseases, highlight deficiencies in 
the existing forms of disease classiﬁcation. 
Although the phenotypic description of a 
family is clearly what initially determines 
the disease classiﬁcation and focuses the 
search for the molecular cause, it is limited 
as a ﬁnal disease classiﬁer. Increasingly, 
it will be important to base the disease 
classiﬁcation on the gene that is mutated. 
Although this is complicated by allelic 
eﬀects, genetic background, and possible 
other complex inheritance, it is the most 
logical basis for classifying genetic diseases 
and an essential starting point for compre-
hensive genotype–phenotype studies.
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Thiazide diuretic monotherapy 
for hypertension: Diuretic’s dark 
side just got darker
BH Rovin1 and LA Hebert1
Diuretic monotherapy is the current recommendation of the Joint 
National Committee on Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure for initial antihypertensive 
therapy. There is mounting concern, however, that the benefits 
of diuretic’s superior blood pressure control may be offset by its 
multiple metabolic disturbances that increase cardiovascular risk. 
Reungjui et al. document a new concern, nephrotoxicity by thiazide 
monotherapy. This and other recently published evidence of 
diuretic’s ‘dark side’ is discussed.
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In this issue of Kidney International, 
Reungjui and colleagues1 convincingly 
show that chronic hydrochlorothiazide 
administration causes focal glomeru-
lar and tubular interstitial injury in 
rats independent of diuretic-induced 
hypokalemia, hyperglycemia, hype-
ruricemia, and blood pressure (BP) 
changes. This work adds signiﬁcantly 
to the list of ‘metabolic dysfunctions’ of 
thiazide diuretic2 that could negate the 
cardiovascular and renal beneﬁts expected 
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of thiazide diuretic therapy because of its 
ability to control both hypertension and 
volume status. The potential for chronic 
thiazide monotherapy to negate its car-
diovascular benefits can be viewed as 
diuretic’s ‘dark side.’3
Because thiazide diuretic therapy has 
the potential to be both good and bad, it 
has been suggested by many (reviewed 
by Hebert et al.3 and Campese4) that diu-
retic should not be the initial choice for 
hypertension management, if only mon-
otherapy is required. Instead, hyperten-
sion monotherapy should involve a drug 
without an obvious dark side, such as an 
angiotensin-converting enzyme inhibitor 
(ACEI).3–5 Nonetheless, largely on the 
basis of the outcome of the Antihyper-
tensive and Lipid-Lowering Treatment 
to Prevent Heart Attack Trial (ALL-
HAT), the Joint National Committee on 
Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure has 
endorsed thiazide (hydrochlorothiazide 
or equivalent thiazide) as ﬁrst-line ther-
apy for most hypertensives.6 Although 
the ALLHAT investigators have acknowl-
edged diuretic’s metabolic perturbations, 
they discount them as clinically signiﬁ-
cant because they did not seem to cause 
harm in ALLHAT.7 Others, however, 
have expressed concern because the diu-
retic cohort did not do as well as might be 
expected considering the diuretic cohort’s 
monopoly on BP and volume control.3,4 
Furthermore, new light has recently been 
shed on diuretic’s dark side by the Trial-
ists’ Collaboration metaanalysis of over 
100,000 patients followed in randomized 
trials of ACEI therapy.8 These issues are 
discussed next.
Evidence for thiazide diuretic’s dark 
side as revealed in ALLHAT and in the 
Trialists’ Collaboration report
ALLHAT compared thiazide (chlortha-
lidone), ACEI (lisinopril), α1-blocker 
(doxazosin), and calcium channel blocker 
(CCB; amlodipine), each as monotherapy 
in hypertensives with cardiovascular 
disease or its risk factors. Entirely on 
the basis of subset analyses, ALLHAT 
declared diuretic the winner. This has 
evoked numerous critical commentaries 
(reviewed by Hebert et al.,3 Campese,4 
Messerli and Kuteyeva,9 and Grimm10).
We suggest that ALLHAT’s favorable 
impression of thiazide diuretic probably 
is due to a study design that biased the 
outcome in favor of the diuretic cohort.3 
Speciﬁcally, ALLHAT is the only major 
hypertension trial that deliberately 
recruited hypertensives with cardio-
vascular disease, and then made diuretic 
one of the randomized therapies. This 
is a design ﬂaw because patients with 
cardiovascular disease are especially 
vulnerable to ﬂuid overload, which can 
(even when incipient) worsen hyper-
tension, pulmonary congestion, and 
myocardial ischemia. Neither ACEI nor 
CCB as monotherapy is recommended 
for volume control. Thus, ALLHAT’s 
design advantaged the diuretic cohort, 
especially at the expense of the ACEI 
cohort. Note that the studies that dem-
onstrated ACEI’s cardiovascular pro-
tection added diuretic to ACEI therapy, 
if needed.8 We refer to this practice as 
‘optimal ACEI therapy.’
Another ALLHAT design flaw is 
that ALLHAT required titration of the 
blinded monotherapy to achieve the BP 
goal. To see how this is a design ﬂaw, 
consider the following. The managing 
physician observes worsening hyper-
tension. Incipient fluid overload is 
suspected. Nevertheless, the physician 
follows study protocol and increases 
the dose of the assigned monotherapy, 
hoping it is a diuretic. Unfortunately, 
it is ACEI or CCB. Over the ensuing 
weeks, fluid retention and hyperten-
sion worsen. The patient returns now 
with an ALLHAT end point (myocar-
dial infarction, congestive heart failure, 
or stroke), which is counted against the 
ACEI or CCB cohort. If standard of 
care had been followed (timely use of 
diuretic), such end points might have 
been avoided.3
The ALLHAT design ﬂaws gave the 
diuretic cohort a monopoly on BP and 
volume control. In so doing, they hid 
diuretic’s dark side. This is revealed by 
an examination of ALLHAT’s primary 
outcome measure, combined non-fatal 
myocardial infarction and fatal coronary 
heart disease (CHD). This showed the 
diuretic and ACEI cohorts in a statistical 
tie (mean CHD risk reduction 0.99, 95% 
conﬁdence interval 0.91–1.08, favoring 
ACEI). The statistical tie is paradoxi-
cal considering the diuretic cohort’s 
signiﬁcantly better BP control (systo-
lic BP 2.5 mm Hg lower overall, 3 mm 
Hg lower in patients >65 years old, and 
4 mm Hg lower in black patients8). 
These large BP diﬀerences should have 
translated into lower CHD risk.8 Also, 
among the randomized monotherapies, 
only diuretic controlled volume status. 
This can inﬂuence CHD risk independ-
ently of BP. For example, increased 
volume status can worsen myocardial 
ischemia by increasing cardiac output, 
or by increasing left ventricular end 
diastolic pressure—thereby decreasing 
subendocardial blood ﬂow. In this light, 
it is remarkable that diuretic could not 
lower CHD risk better than ACEI. This 
is clear evidence of diuretic’s dark side.
The strongest evidence of diuretic’s 
dark side is provided by the recent Tri-
alists’ Collaboration report.8 This is 
an advance over the previous relevant 
metaanalyses because an additional 
48,745 patients were available for 
study, and more sophisticated statisti-
cal techniques were used.8 The Trialists’ 
key ﬁnding is that, in comparison to 
the comparator therapies (diuretic, β-
blocker, or CCB), ACEI is associated 
with a 9% reduction in major CHD 
events (95% conﬁdence interval 3%–
14%, P = 0.004), which is independent 
of BP control. Further detail is provided 
in Figure 1. ALLHAT did not describe 
a BP-independent beneﬁt of ACEI (Fig-
ure 1, Box 1), probably because, of the 
randomized ACEI trials, only ALLHAT 
did not use ACEI optimally (with diu-
retic if needed).
The Trialists’ report also reveals diu-
retic’s dark side as follows. If, at a given 
level of BP reduction, diuretic was just 
as effective in lowering CHD risk as 
optimal ACEI therapy—the lower line 
in Figure 1—then the 2.5-mm Hg-lower 
BP in the ALLHAT diuretic cohort ver-
sus its comparator (non-optimal ACEI 
therapy) should have reduced CHD risk 
by nearly 20% (Figure 1, Box 3). In fact, 
in ALLHAT the mean CHD risk reduc-
tion comparing the diuretic cohort to 
the ACEI cohort was a non-signiﬁcant 
1%, and it favored the ACEI cohort 
(Figure 1, Box 2). Furthermore, the 
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lower conﬁdence interval for CHD risk 
reduction for diuretic versus ACEI was 
7%, far less than the nearly 20% CHD 
risk reduction expected based on diuret-
ic’s 2.5-mm Hg-better BP control. This 
analysis does not even take into account 
diuretic’s monopoly on volume control. 
Clearly diuretic has a dark side relative 
to ACEI that can negate diuretic’s car-
diovascular beneﬁts achieved by BP and 
volume control.
Mechanisms of diuretic’s dark side
Thiazide diuretics induce hypokalemia, 
hyperlipidemia, hyperuricemia, and 
stimulation of the renin–angiotensin 
system, all of which probably increase 
cardiovascular risk (reviewed by Hebert 
et al.3). An appealing hypothesis is that 
the diuretic-induced increased aldoster-
one levels may be vasculotoxic through 
genomic and non-genomic mecha-
nisms.11 This could mediate, in part, 
diuretic’s renal dark side elucidated 
by Reungjui et al.,1 and diuretic’s 
cardiovascular dark side elucidated by 
the Trialists’ Collaboration.8
Hemodynamic eﬀects could also be 
involved in thiazide’s dark side. ACEI 
and diuretic comparably reduce brachial 
artery pressure; however, diuretic main-
tains a higher central aortic pressure,12 
which can increase cardiovascular risks.
Clinical implications of diuretic’s dark side
In routine hypertension management, thi-
azide monotherapy is worrisome in young 
hypertensives, who might be exposed 
to diuretic for decades,4 and in obese 
hypertensives, whose metabolic syn-
drome can be exacerbated by diuretic.13 
Thus, a strong case can be made for initial 
therapy with ACEI, followed by diuretic 
if needed.3,4 When ACEI and diuretic 
therapy are combined, diuretic’s dark-side 
mechanisms probably are mitigated.3
In chronic kidney disease (CKD) 
management, diuretic therapy is often 
needed to control volume status and BP. 
Nevertheless, in both the Modiﬁcation of 
Diet in Renal Disease (MDRD) trial and 
the African American Study of Kidney 
Disease and Hypertension (AASK), about 
half of CKD patients did not receive 
diuretics, yet generally they achieved 
their BP goals.14 Perhaps overzealous 
use of diuretics in CKD management 
accounts for the reported association of 
greater diuretic use with faster decline 
in glomerular ﬁltration rate.15 Thus, the 
ideal may be to reduce salt intake rather 
than to ‘push’ diuretics.14
If diuretic is needed, chlorthalidone 
(half-life about 50 hours) can be rec-
ommended, because it is about twice as 
potent at lowering BP as hydrochloro-
thiazide (half-life about 6 hours).4 Loop 
diuretics are more effective in CKD 
than thiazide diuretics.14 Whether loop 
diuretics carry less risk than thiazide 
diuretics is not clear. However, loop 
diuretics share at least some of thiazide’s 
metabolic dysfunctions.1
Those who favor diuretics as pri-
mary hypertension management point 
Figure 1 | Association of BP reduction with risk reduction for fatal and non-fatal myocardial infarction in randomized trials of angiotensin-
converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) against a comparator therapy (diuretic, β-blocker, or calcium channel 
blocker). The fitted lines represent the summary meta-regressions for the outcomes of the ACEI trials (lower line) and the ARB trials (upper line). See 
Boxes 1, 2, and 3 for further analysis. The ACEI trials' meta-regression line can be regarded as the 'optimal ACEI therapy' line, because all trials, except 
ALLHAT, used ACEI optimally (with diuretic, if needed). (Adapted from ref. 8.)
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1  Evidence for BP-independent effects of ACEI in coronary heart disease. 
ACEI is associated with a 9% coronary heart disease (CHD) risk reduction (95% 
confidence interval 3%–14%, P = 0.004). ALLHAT did not find this, probably 
because in ALLHAT ACEIs were not used optimally (with diuretic, if needed).
2  Diuretic versus ACEI in ALLHAT. 
BP was higher in the ACEI cohort than in the diuretic cohort, 
but the CHD outcomes for the cohorts were the same. This is 
evidence of diuretic’s dark side in relationship to ACEI.
3  Theoretical CHD risk reduction by 
diuretic in ALLHAT if diuretic was as 
protective against CHD as ACEI used 
optimally. 
In ALLHAT, systolic BP was 2.5 mm Hg 
lower in the diuretic than in the ACEI 
cohort. Thus, if reduction of BP by 
diuretic was just as effective as that by 
optimal ACEI therapy in reducing CHD 
risk, the 2.5-mm Hg-greater BP 
reduction by diuretic than by its 
comparator (non-optimal ACEI) should 
have reduced CHD risk by nearly 20% 
(arrow). This did not occur (see Box 2). 
This is evidence of diuretic’s dark side 
relative to optimal ACEI therapy.
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out diuretic’s lower cost as compared 
with ACEI, and that many of diuretic’s 
metabolic dysfunctions are treatable.10 
However, treating diuretic’s metabolic 
dysfunctions also incurs cost. An even 
greater cost is incurred if diuretic’s meta-
bolic dysfunctions go untreated because 
they are unrecognized or because the 
patient cannot aﬀord the treatment. In 
this context, ACEI is a bargain, particu-
larly generic ACEI.3
ACKNOWLEDGMENTS
This work was supported in part by National 
Institutes of Health grants PO1 DK55546, 
UO1 DK48621, and MO1 RR00034.
REFERENCES
1. Reungjui S, Hu H, Mu W et al. Thiazide-induced 
subtle renal injury not observed in states of 
equivalent hypokalemia. Kidney Int 2007; 72: 
1483–1492.  
2. Houston MC. ALLHAT debate: diuretics are 
not preferred, first-line initial therapy for 
hypertension. Arch Intern Med 2004; 164: 570–
571; author reply 571–572.
3. Hebert LA, Rovin BH, Hebert CJ. The design of 
ALLHAT may have biased the study’s outcome 
in favor of the diuretic cohort. Nat Clin Pract 
Nephrol 2007; 3: 60–61.
4. Campese VM. Diuretics are preferred over 
angiotensin II-converting enzyme inhibitors for 
initial therapy of uncomplicated hypertension. 
Am J Kidney Dis 2007; 50: 197–202.
5. Messerli FH, Grossman E, Leonetti G. 
Antihypertensive therapy and new onset 
diabetes. J Hypertens 2004; 22: 1845–1847.
6. Chobanian AV, Bakris GL, Black HR et al. The 
Seventh Report of the Joint National Committee 
on Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure: the JNC 7 
report. JAMA 2003; 289: 2560–2572.
7. Davis BR, Furberg CD, Wright JT Jr. et al. ALLHAT: 
setting the record straight. Ann Intern Med 2004; 
141: 39–46.
8. Turnbull F, Neal B, Pfeffer M et al. Blood pressure-
dependent and independent effects of agents 
that inhibit the renin-angiotensin system.  
J Hypertens 2007; 25: 951–958.
9. Messerli FH, Kuteyeva O. Bashing diuretics or 
failure of surrogate endpoint? J Hypertens 2007; 
25: 949–950.
10. Grimm R. Diuretics are preferred over 
angiotensin II-converting enzyme inhibitors for 
initial therapy of uncomplicated hypertension. 
Am J Kidney Dis 2007; 50: 188–196.
11. Haddad N, Rajan J, Nagaraja HN et al. Usual ACE 
inhibitor therapy in CKD patients is associated 
with lower plasma aldosterone levels than usual 
angiotensin receptor blocker therapy. Kidney 
Blood Press Res 2007; 30: 299–305.
12. Jiang XJ, O’Rourke MF, Zhang YQ et al. Superior 
effect of an angiotensin-converting enzyme 
inhibitor over a diuretic for reducing aortic systolic 
pressure. J Hypertens 2007; 25: 1095–1099.
13. Scholze J, Grimm E, Herrmann D et al. Optimal 
treatment of obesity-related hypertension: the 
Hypertension-Obesity-Sibutramine (HOS) study. 
Circulation 2007; 115: 1991–1998.
14. Wilmer WA, Rovin BH, Hebert CJ et al. Management 
of glomerular proteinuria: a commentary. J Am Soc 
Nephrol 2003; 14: 3217–3232.
15. Hawkins RG, Houston MC. Is population-wide 
diuretic use directly associated with the 
incidence of end-stage renal disease in the 
United States? A hypothesis. Am J Hypertens 
2005; 18: 744–749.
